# To Evaluate the Safety and Efficacy of Ipatasertib (GDC-0068) in Combination With Paclitaxel in Platinum-resistant Recurrent Epithelial Ovarian Cancer

> **NCT04561817** · PHASE2 · WITHDRAWN · sponsor: **Icahn School of Medicine at Mount Sinai**

## Conditions studied

- Ovarian Neoplasms

## Interventions

- **DRUG:** Ipatasertib
- **DRUG:** Paclitaxel

## Key facts

- **NCT ID:** NCT04561817
- **Lead sponsor:** Icahn School of Medicine at Mount Sinai
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2020-10-01
- **Primary completion:** 2022-10-01
- **Final completion:** 2023-10-01
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Evolving data with Ipatasertib that changes the known risk / benefit background in pursuing future studies.
- **Last updated:** 2020-10-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04561817

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04561817, "To Evaluate the Safety and Efficacy of Ipatasertib (GDC-0068) in Combination With Paclitaxel in Platinum-resistant Recurrent Epithelial Ovarian Cancer". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04561817. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*